Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) (Q61981266)

From Wikidata
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
clinical trial
Language Label Description Also known as
English
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
clinical trial

    Statements

    short name
    Cloric (English)
    0 references
    title
    A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-risk AML, MDS or ALL. (English)
    0 references
    country
    France
    0 references
    start time
    October 2009
    0 references
    end time
    June 2013
    0 references
    number of participants
    30
    0 references
    minimum age
    18 year
    0 references
    maximum age
    65 year
    0 references

    Identifiers

     
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q61981266&oldid=2212747273"